RxDoctor Payments Data

Jack Stroh, MD

Interventional Cardiology · Somerset, NJNPI 1356347066

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $46,881 of the $62,244 with a category attached, or 75.3%. 19 manufacturers reported payments, led by Amarin Pharma, Inc. at 50.1% of the total. Reporting peaked in 2019 at $36,380 and has fallen 100.0% since, to $16 in 2024. Among interventional cardiology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,244in general payments, 2019–2025

Across 365 payments — averaging $170.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$31K
  • Esperion Therapeutics, Inc.$10K
  • Sanofi-aventis U.S. LLC$6K
  • Medtronic$6K
  • Regeneron Healthcare Solutions, Inc.$5K
  • E.r. Squibb & Sons, L.L.C.$942
  • plus $3K from 13 others

What the payments were for

  • Speaking & faculty fees$46,88175%
  • Travel & lodging$8,48614%
  • Food & beverage$6,83411%
  • Education$430%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,244 in reported general payments places this provider in the 90th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$6,115
Medicare patients
47
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$91,404
EntrestoSacubitril/Valsartan31$46,610
XareltoRivaroxaban13$20,100
VascepaIcosapent Ethyl18$13,071
Repatha SureclickEvolocumab14$10,506
Icosapent Ethyl12$8,055
Nebivolol Hcl40$2,477
Rosuvastatin Calcium170$2,251
Ranolazine ErRanolazine20$2,215
Ezetimibe80$2,111
Metoprolol Succinate76$1,142
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide38$1,089
Atorvastatin Calcium85$927
Bisoprolol Fumarate35$926
ClopidogrelClopidogrel Bisulfate62$915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$258$91,40497 claims
NovartisEntresto$471$46,61031 claims
Johnson & JohnsonXarelto$817$20,10013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Somerset

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →